API
JAZZ icon

Advisor Partners II’s Jazz Pharmaceuticals JAZZ Stock Holding History

Advisor Partners II’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$231K Buy
+1,786
New +$238K 0.01% 1096
2023
Q2 		– Sell
-1,895
Closed -$277K – 1104
2023
Q1 		$277K Buy
1,895
+538
+40% +$79.6K 0.02% 771
2022
Q4 		$216K Buy
+1,357
New +$199K 0.01% 824

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Advisor Partners II's JAZZ Position: Q3 2023 in Review

Advisor Partners II opened a new position in Jazz Pharmaceuticals (JAZZ) in Q3 2023: 1,786 shares worth $231K. The stake represents 0.01% of the portfolio and ranks #1096 among its holdings. This is a return to the name: Advisor Partners II previously reported a position in JAZZ as recently as Q1 2023.

Advisor Partners II first reported a position in JAZZ in Q4 2022 and has held it in 3 quarters since. The position peaked at $277K in Q1 2023. 484 funds tracked by Wall St. Rank hold JAZZ as of Q3 2023.

  • Advisor Partners II held 1,786 shares of Jazz Pharmaceuticals worth $231K as of Q3 2023.
  • Jazz Pharmaceuticals was a new Advisor Partners II position in Q3 2023.
  • Jazz Pharmaceuticals made up 0.01% of Advisor Partners II's portfolio in Q3 2023, its #1096 holding.
  • Advisor Partners II first reported a position in Jazz Pharmaceuticals in Q4 2022 and has held it in 3 quarters since.
  • Advisor Partners II's Jazz Pharmaceuticals position peaked at $277K in Q1 2023.
  • 484 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2023.

Based on Advisor Partners II's 13F filing for Q3 2023, filed 26 Oct 2023.